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Abstract:
Purpose:
The aim of this study was to compare the use of two or more high-potency anticholinergic
(HPA) medications between patients 65 years and older in nursing homes and in the greater
community using prescribing data.
Methods:
This secondary data analysis of the NHS Scotland PIS databased used prescription data
from a nationally representative patient-level database. Patients were included were ≥65
years old, received ≥2HPA prescriptions from 2011Q2-2012Q1(11/12), 2016Q12017Q2(16/17), 2018Q2-2017Q1(18/19). The principle endpoint of this study was to
assess for a change in patient’s relative risk of receiving ≥2HPA prescriptions.
Results:
29,301 patients were identified. From 11/12 to 16/17 all community ≥65 years of age, and
nursing home patients 65-74, 75-84 showed a relative risk reduction. 16/17 to 18/19,
community patients 65-74 years and ≥85 no significant change in relative risk and 75-84
showed a relative risk increase. 16/17 to 18/19 nursing home patients 65-74 relative risk
reduction and 75-84 no significant change. 16/17 to 18/19 nursing home patients aged ≥85
experienced a relative risk increase.
Conclusion:
Nursing home patients ≥85 years in 2018/2019 showed an increase in relative risk from
patients in 2016/17, this group may still be at risk for the high anticholinergic burden.
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Acronyms and Abbreviations:
Q1’2011 – Q2’2012 (11/12)
Q1’2016 – Q2’2017 (16/17)
Q1’2018 – Q2’2019 (18/19)
American Geriatric Society (AGS)
British National Formulary (BNF)
Community Health Index (CHI)
High Potency Anticholinergic (HPA)
Information Services Division (ISD)
Modified Anticholinergic Risk Scale (mARS)
National Health System (NHS)
National Institute for Health and Care Excellence (NICE)
National Therapeutic Indicators (NTI)
Prescription Information System (PIS)
Unique Patient Identifier (UPI)
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Introduction:
Medications with anticholinergic properties antagonize the neurotransmitter
acetylcholine by competitively binding to the muscarinic and nicotinic receptors (Nishtala
et al., 2016). Anticholinergic receptors are proliferative throughout the body and play an
essential role in cognitive processing and movement (Svoboda et al., 2017). This
mechanism of action is utilized directly in the treatment of Parkinson’s Disease,
schizophrenia, incontinence, and Alzheimer’s disease (Svoboda et al., 2017). However,
other medications such as antidepressants, antipsychotics, and antihistamines have
anticholinergic properties outside of the direct mechanism of action. In this case, the
anticholinergic effect of these medications manifests as anticholinergic side effects. Table
1 identifies the most common anticholinergic side effect and their subsequent
consequences.

Medications with a strong antagonism of the muscarinic receptors have more
significant anticholinergic side effects (Mulsant et al., 2003). Additionally, using several
anticholinergic medications concurrently increases the significance of side effects through
cumulative exposure (Mulsant et al., 2003). Researchers quantify this effect by analyzing
the serum anticholinergic activity (Mulsant et al., 2003). For clinical purposes,
anticholinergic risk scales (ARS) identify patients at risk of side effects through
quantifying the anticholinergic burden. The NHS Scotland polypharmacy guidelines utilize
the modified Anticholinergic Risk Scale (mARS) to categorize medications available in
the United Kingdom on a scale of 0-3 of anticholinergic potential (PrescQIPP, 2016). A
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score of 0 indicates limited or none, 1- moderate, 2- strong, and 3- very strong
anticholinergic potential (PrescQIPP, 2016).

Side Effect

Consequences

Peripheral
Decreased Sweating

Thermoregulatory impairment leading to hypothermia

Decreased Salivation

Dental decay, periodontal disease, ulceration of gums,
difficulty chewing and swallowing, respiratory infections,
denture misfit, mucosal damage

Urinary Hesitancy
Decreased Gastrointestinal
Motility
Dilation of Pupils

Urinary retention, urinary tract infection, bladder distention
Constipation, decreased gastric emptying, fecal impaction
Photophobia, precipitation of acute narrow angle glaucoma,
dizziness, vision disturbances
Angina, myocardial infarction, conduction disturbances

Increased Heart Rate
Central
Impaired Concentration,
Exacerbation of cognitive impairment
Confusion, Attention
Deficient, Memory
Impairment
Table 1: Anticholinergic Side Effects (Mintzer & Burns, 2000; Libermann, 2004)

Anticholinergic side effects can be devastating in older adults and result in
decreased quality of life. As shown in Table 1, side effects can be both central and
peripheral. Several studies described this phenomenon in elderly individuals (Liberman,
2004; Flacker, 1998; Tune, 2001; Feinberg, 1993). This disproportionate effect in the
elderly community arises not only from the nature of the side effects but several other
reasons. Older individuals are more likely to have chronic conditions such as angina,
diabetes mellitus, constipation, glaucoma, urinary dysfunction, sleep disturbances, and
dementia that may be exacerbated by a high anticholinergic burden (Feinberg, 1993).
Aging results in changes in pharmacokinetics and pharmacodynamics, such a 30%
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decrease in hepatic clearance and 50% decrease in renal clearance (Koltz, 2009). These
changes may result in increased sensitivity to medications.

Of particular concern in the geriatric community is the potential for a high
anticholinergic burden to worsen delirium and amply cognitive decline. Ancelin et al., in a
study of individuals aged 60 years and older without baseline dementia, found that older
individuals with a high anticholinergic burden had deficits in cognition (2006). Britt &
Gregory, in their 2016 systematic review, found similar findings demonstrating that the use
of anticholinergic medications is associated with adverse cognitive effects in cognitively
healthy individuals, and more so in individuals with preexisting cognitive impairment
(2016). Finally, the most common cause of drug-induced delirium is highly anticholinergic
medications (Tune, 2001).

Elderly patients residing in nursing homes are another subsection of the geriatric
population at particularly high risk for an increased anticholinergic burden. In comparison
to older patients living in the community, nursing home patients are more likely to have
more comorbid conditions and decreased functional status. The 1983 study by Blazer et
al., compared Tennessee Medicaid recipients aged 65 years and older living in the
community and nursing homes. Among nursing home patients, 59% received at least one
drug with anticholinergic properties. In comparison, 23% of community patients received
at least one drug with anticholinergic properties (Blazer, 1983). More concerning, 10-17%
of nursing home patients received three or more anticholinergic medications (Blazer,
1983). Of note, this study was conducted in 1983 before widespread attention was brought
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to this cause by the medical community. Therefore, these results may be an overestimation
in today’s standards. Similarly, a 2016 study of Veterans aged 65 years and older residing
in nursing homes found among residents with dementia or cognitive impairment 50.7%
took medications that could exacerbate cognitive impairment, with the most common
medicines antipsychotics at 35.4% (Aspinall et al. 2015). Many antipsychotics and
antidepressant drugs have a high anticholinergic burden, yet in a study of 3,000 nursing
home patients, 43% used at least one psychotropic agent (Spore et al., 1993). Therefore,
the literature suggests that nursing home patients are acutely vulnerable to receiving a high
anticholinergic burden.

In the United States, the American Geriatric Society (AGS) produces the AGS
Beers Criteria to identify medications that are potentially inappropriate for use in older
individuals. The 2019 Beers Criteria identifies highly anticholinergic medications such as
first-generation antihistamines, antispasmodics, skeletal muscle relaxants as potentially
inappropriate medications for use in older individuals (American Geriatrics Society, 2019).
The guidelines recommend avoiding the use of multiple anticholinergic agents due to the
risk of cognitive decline (American Geriatrics Society, 2019). Additionally, it is
recommended to avoid the use of highly anticholinergic medications in patients with
dementia or at risk of developing dementia due to the potential of inducing or worsening
dementia (American Geriatrics Society, 2019). However, use of the Beers Criteria is
limited to mediations currently available on the US market. In the United Kingdom, several
sources provide recommendations around the use of anticholinergic medications. The
Scottish Government published the 2018 Polypharmacy Guidance, Realistic Prescribing
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outlining strategies to mitigate the potentially harmful effects of polypharmacy in older
individuals. This guideline recommends reducing the anticholinergic burden in patients
through avoiding or deprescribing highly anticholinergic medications and avoiding the
combination of multiple anticholinergic medications (Scottish Government Polypharmacy
Model of Care Group, 2018). In England, the National Institute for Health and Care
Excellence (NICE) 2018 guidelines on dementia states that highly anticholinergic
medications may cause cognitive impairment (2018). NICE guidance on dementia
diagnosis recommends to identify cognitive decline due to anticholinergic medications and
to minimize the anticholinergic burden (2018). Further research is needed to determine if
reducing the anticholinergic burden in those with dementia improve cognitive outcomes
compared to usual care (NICE, 2018).

Within Scotland, the National Health System (NHS) utilizes National Therapeutic
Indicators (NTI) to produce further guidance on the use of anticholinergic medications in
elderly individuals. To develop NTIs, the Information Services Division (IDS) Scotland
uses the Prescription Information System (PIS). This database consists of prescription data
from all 5.3 million individuals utilizing the NHS Scotland System (IDS Scotland). The
Health Boards/Health and Social Care Partnerships then use NITs to direct prescribing
actions throughout Scotland (Information Services Division Scotland). The 2018 NTI
looked at preventing falls, fracture, and delirium through analyzing “the number of people
aged ≥75 years dispensed >10 items of strong or very strong anticholinergics (mARS 2&3)
per annum as a percentage of all people ≥75 years” (NHS Scotland, 2018). This analysis
showed that the prescribing of strong anticholinergics to older individuals had decreased
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slightly over the last three years (NHS Scotland, 2018). This NTI observed trends within
the NHS prescribing boards, or regions, but did not further stratify the data by age or
residency status to explore if a difference exists among patients residing in the community
or nursing homes.

The purpose of this analysis is to further the work of NHS Scotland’s 2018 NTI
regarding the use of anticholinergic medications in elderly individuals. The objective is to
compare the use of two or more high-potency anticholinergic (HPA) medications among
patients 65 years and older in nursing homes and the greater community using prescribing
data. Stratification of anticholinergic prescribing by age and residency status allows for a
closer examination of the data and the potential to identify which Scottish patients may
benefit from further review of anticholinergic medication use. The endpoint of this study
is to assess for a change in a patient’s relative risk of receiving more than 2 HPA
prescriptions from 2011 to 2019.
Methods:
Dataset:
Data for this study was obtained from the PIS dataset. This comprehensive
prescription claims dataset includes all community prescriptions dispensed and claimed for
reimbursement by the 5.3 million Scottish citizens who currently use the NHS Scotland.
Excluded from this dataset are prescriptions dispensed in hospitals. Within the PIS dataset
is information on prescriber, dispenser, patient, organizational structure, and drug
information. This dataset is maintained by the ISD.
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Notable elements include unique patient identifier (UPI) and community health
index (CHI) capture. UPI is a unique number assigned to patients to link prescription events
and therefore quantify the number of patients receiving a particular medication in a deidentified manner. CHI capture rate is a surrogate measure to guarantee that each
prescription captured is valid, and therefore assess the completeness of the PIS database.
As of 2016, the CHI capture rate was almost 100%, indicating the dataset is an accurate
representation of community prescribing within NHS Scotland.

Population Estimates:
Control data of patients not receiving ≥2HPA prescriptions were obtained through
population estimates. The Scottish government does not keep an annual nursing home
patient census. To estimate the total number of patients living in nursing homes the PIS
database was queried to find the number of patients aged ≥65, residing in nursing homes,
and receiving at least one prescription. This data was further stratified by 10-year age
bands. The number of patients not receiving ≥2HPA prescriptions residing in the
community was obtained through National Records of Scotland mid-year population
estimates of 2011, 2016, and 2018. This data was pre-stratified into 5-year age bands
(2020). Finally, the number of patients not receiving ≥2HPA prescriptions in nursing
homes was subtracted to arrive at the final number of community patients.

Definition of High-Potency Anticholinergic Medications:
Medications were defined as HPA based on the mutual inclusion in the 2018 NTI
“Falls, fractures, and delirium” and mARS class 3. Inclusion of mARS class 3 medications
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ensures this study examined only those medications with the highest potential to cause
anticholinergic side effects. A comprehensive list of medication is included in the
appendix. The identified medications were sorted into the corresponding British National
Formulary (BNF) paragraphs. The British National Formulary is a publication which
categorizes all available formulary medications into a coded hierarchy. The paragraph
indicates the medication’s class. This step prevented inaccurate counts resulting from
patients switching from drugs within the same class.

Sampling and Analytical Strategy:
Using SAP Business Objects BI Platform 4.2 the PIS database was processed by
building quires to extract specific data. The first query applied the following filters to build
the core group of patients: (1) over 65 years of age (2) valid CHI capture (3) prescriber
located within one of the 14 Scottish Health Boards (4) captured within the calendar
year/quarters Q2 2011-Q1 2012 (11/12), Q2 2016-Q1 2017 (16/17), Q2 2018-Q1 2019
(18/19) (5) HPA BNF paragraph. To create the two groups of interest, “nursing home
residency” and “community residency”, the core group was stratified by nursing home
residency. Next, utilizing UPI’s each group was quired to quantify how many patients
received ≥2HPA prescriptions. Finally, each group was separated into the following 10year age bands: 65-74, 75-85, and over 85.
To visualize a change in number of patients receiving ≥2HPA prescriptions, the
rate of patient’s receiving ≥2HPA prescriptions per 1000 patients was calculated for each
10 year age band within the specified residency status using Microsoft Excel 16.35. To
assess if a statistically significant change in patient’s relative risk of receiving ≥2 HPA
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prescriptions occurred the risk ratio and relative risk reduction from 11/12 to 16/17 and
16/17 to 18/19 was calculated. Open Epi was used for all statistical comparisons (Dean,
Sullivan, Soe, 2013)

Results:
During the specified time, 29,301 patients aged ≥65 were identified to receive ≥2
HPA prescriptions. Of 9,303 patients identified in 18/19, 7% resided in nursing homes
(Table 2). Among total nursing home patients identified to receive ≥2HPA prescriptions in
18/19, 15% were aged 65-74, 23% were 75-84, and 62% were over 85 years old (Table 2).
Among total community patients identified to receive ≥2HPA medications in 18/19, 42%
were 65-74, 23% were 75-84, and 23% were over 85 years old (Table 2). These patterns
are reflected in 11/12 and 16/1,7 as shown in Table 2.

65-74
Q2 2011 – Q1 2012
Nursing Home (n=574)
Community(n= 10656)

89 (15%)
4460 (42%)

75-84

85+

130 (23%)
3774 (35%)

355 (62%)
2422 (23%)

172 (30%)
2827 (34%)

285 (51%)
798 (10%)

Q2 2016 – Q1 2017
Nursing Home (n=560)
Community (n=8208)

103 (18%)
4583 (56%)

Q2 2018 – Q1 2019
95 (16%)
178 (30%)
315 (54%)
Nursing Home (n=588)
4753 (55%)
3061 (35%)
901 (10%)
Community (n=8715)
Table 2: Number of patients receiving ≥2HPA prescriptions and percentage of
patients receiving ≥2HPA prescriptions stratified by age band and residency status
(n=29,301)
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Q2’11-Q1’12
38.1

Q2’16-Q1’17
26.3

Q1’18-Q2-19
19.2

9.4

8.4

8.4

Nursing Home 7584
Community 75-84

18.5

14.3

12.7
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9.4

9.6

Nursing Home 85+

10.9

11.3

15.6

Community 85+

53.6

1.6

8.7

Nursing Home 6574
Community 65-74

Table 3: Rate of ≥2 HPA prescriptions per 1000 residents of nursing homes or
community, respectively, stratified by age band.

40
35
30
25
Rate per 1000 20

Nursing Home Patients

15

Community patients

10
5
0
Q2 2011-Q1
2012

Q2 2016-Q1
2017

Q2 2018-Q1
2019

Figure 1: Rate of patients aged 65-74 receiving ≥2 HPA prescriptions stratified by
residency
11/12 to 16/17
16/17 to 18/19
Relative Risk
Relative Risk
Relative Risk
Relative Risk
(RR)
Change (RRR) (RR)
Change (RRR)
Nursing
0.69 (0.52, 0.91) 31% reduction 0.74 (0.60,
26% reduction
homes
p=0.0050
0.97) p=0.015
Community 0.89 (0.85, 0.93) 11% reduction 1.01 (0.97,
NS
p <0.000001
1.05) p=0.29
Table 4: Relative risk ratio and relative risk reduction for patients aged 65-74
stratified by residency status
NS= Indicates not statistically significant results
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Looking at patients aged 65-74, the rate of nursing home patients receiving ≥2 HPA
prescriptions was 38.1 per 1000 patients in 11/12, 26.3 per 1000 in 16/17, and 19.2 per
1000 in 18/19 (Table 3, Figure 1). Among those residing in the community, the rate of
patients receiving ≥2 HPA prescriptions was 9.4 per 1000 in 11/12, 8.4 per 1000 in 16/17,
8.4 per 1000 in 18/19 (Table 3, Figure 1). This corresponds to nursing home patients in
16/17 had 31% less risk of receiving ≥2 HPA prescriptions compared to patients in 11/12
(Table 4). Then, nursing home patients in 18/19 had 26% less risk of receiving ≥2 HPA
prescriptions compared to patients in 16/17 (Table 4). Community patients in 16/17 had
11% less risk of being prescribed ≥2 HPA medications compared to patients in 11/12, and
community patients in 18/19 had a non-statistically significant change in relative risk
(Table 4).

20
18
16
14
12
Rate per 1000 10
8
6
4
2
0

Nursing Home Patients
Community Patients

Q2 2011-Q1 2012 Q2 2016-Q1 2017 Q2 2018-Q1 2019

Figure 2: Rate of patients aged 74-84 receiving ≥2 HPA prescriptions stratified by
residency
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11/12 to 16/17
16/17 to 18/19
Relative Risk
Relative Risk
Relative Risk
Relative Risk
(RR)
Change (RRR) (RR)
Change (RRR)
Nursing
0.77 (0.62, 0.97) 23% reduction 0.89 (0.72, 1.10) NS
Homes
p=0.013
p=0.14
Community 0.71 (0.68, 0.75) 29% reduction 1.06 (1.01, 1.12) 6.2% increase
p <0.01
p=0.01
Table 5: Relative risk ratio and relative risk reduction for patients aged 75-84
stratified by residency status
NS= Indicates not statistically significant results
In patients aged 75-84, the rate of nursing patients receiving ≥2HPA prescriptions
per 1000 patients was 18.5 per 1000 in 11/12, 14.3 per 1000 in 16/17, and 12.7 per 1000 in
18/19 (Table 3, Figure 2). For community patients, the rate of patients receiving ≥2 HPA
prescriptions was 13 per 1000 patients in 11/12, 9.4 per 1000 in 16/17, and 9.6 per 1000 in
18/19 (Table 3, Figure 2). Comparing these values to the change in relative risk, nursing
home patients aged 75-84 in 16/17 had 23% less risk of being prescribed ≥2 HPA
medications compared to patients in 11/12 (Table 5). The change in relative risk for nursing
home patients in 16/17 to 18/19 was statistically insignificant. Further, community patients
aged 75-84 in 16/17 had 29% less of being prescribed ≥2 HPA medications risk compared
to patients in 11/12 (Table 5), and community patients in 18/19 had 6.2% more risk of
being prescribed ≥2 HPA medications than those in 16/17.
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60
50
40
Nursing Home Patients

Rate per 1000 30

Community Patients

20
10
0
Q2 2011-Q1 2012 Q2 2016-Q1 2017 Q2 2018-Q1 2019

Figure 3: Rate of patients aged 85 and older receiving ≥2 HPA prescriptions
stratified by residency
11/12 to 16/17
16/17 to 18/19
Relative Risk
Relative Risk
Relative Risk
Relative Risk
(RR)
Change (RRR)
(RR)
Change (RRR)
Nursing
0.98 (0.84, 1.15) NS
1.37 (1.17, 1.60) 37% increase
Homes
p=0.41
p <0.01
Community 0.27 (0.25, 0.30) 72% reduction
1.02 (0.93, 1.13) NS
p<0.01
p=0.33
Table 6: Relative risk ratio and relative risk reduction for patients aged 85 years
and older stratified by residency status
NS= Indicates not statistically significant results
Among community patients aged ≥85, the rate of nursing home patients receiving
≥2 HPA prescriptions was 10.9 per 1000 in 11/12, 11.3 per 1000 in 16/17, and 15.6 per
1000 in 18/19 (Table 3, Figure 3). The rate of community patients receiving ≥2HPA
prescriptions was 53.6 per 1000 in 11/12, 1.6 per 1000 in 16/17, and 8.7 per 1000 in 18/19
(Table 3, Figure 3). Further, from 11/12 to 16/17 nursing home patients over 85 years old
had a statistically insignificant change in risk of receiving ≥2HPA prescriptions (Table 6).
Nursing home patients in 18/19 had a 37% more risk of being prescribed ≥2HPA
medications than those in 16/17 (Table 6). Community patients over 85 years old in 16/17
had 72% less risk of receiving ≥2HPA prescriptions than those in 11/12, and from 16/17
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to 18/19 patients had a statistically insignificant change in the risk of being prescribed
≥2HPA medications (Table 6).

Discussion:
When looking at the number of patients identified as receiving ≥2HPA
prescriptions, the percentage of nursing home patients is consistently smaller than those in
the community. One would expect this trend, considering regardless of HPA use, more
patients reside in the community versus nursing homes. However, it is of particular interest
to note the contrasting trends in age band and residency status. Across all three time
periods, the majority of nursing home patients receiving ≥2HPA prescriptions were over
85 years old. In comparison, the majority of community patients receiving ≥2HPA
prescriptions were 65-74 years old. Again, this trend is expected; older patients are frailer
with more complex conditions and, therefore, more likely to take several medications.
Further, many of the HPA medications identified are antispasmodics or antipsychotics,
utilized commonly in the older population for symptomatic control. Based on these
assumptions, one would expect to see the rate of HPA medication use increase with age.

To begin discussing trends from 11/12 to 16/17, nursing home patients aged 65-84
and community patients aged ≥65 experienced a decrease in the rate of receiving ≥2HPA
prescriptions. For these patients, the reduction in rates corresponds to a significant relative
risk reduction. Meaning nursing home patients 65-84 and community patients ≥65 in 16/17
had less risk of receiving ≥2HPA prescriptions compared to the patients in 11/12. In
continuation of this trend, nursing home patients aged 65-74 in 18/19 experienced a further
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decline in rates and significant relative risk reduction compared to patients in 16/17.
Relative risk reductions and a decrease in rates coincide with the implementation of NHS
advice (2015-2017) to decrease the number of HPA medications prescribed to older adults.
Therefore, the decline seen may suggest the beneficial effects of the NHS initiatives. In
contrast, nursing home patients aged ≥85 from 11/12 to 16/17 showed a non-statistically
significant change in relative risk and a small reduction in rates.

Next, from 16/17 to 18/19, one can see three different trends. First, in continuation
of the trend seen above, nursing home patients aged 65-74 had a further decline in rates
and relative risk reduction. Second, nursing home patients aged 75-84, community patients
aged 65-74 and ≥85 years showed a non-statistically significant change in relative risk.
This non-statistically significant change in relative risk suggests a plateau in the NHS
efforts to decrease HPA prescribing among older adults. Meaning, the initial NHS advice
reached its maximum effect, and all patients able deprescribed from HPA medications.
Third, community patients 75-84 in 18/19 showed more risk of receiving ≥2HPA
medications compared to patients in 16/17. The small relative risk increase in this
population is concerning but mitigated by the fact that in previous years, 11/12 to 16/17,
this same population showed a relative risk reduction. This small increase in rates suggests
that this group needs further NHS guidance to maintain the reduction in relative risk seen
in earlier years.

Finally, nursing home patients aged ≥85 in 18/19 showed increased rates and
significantly more risk of receiving ≥2HPA prescriptions compared to patients in 16/17.
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These results are concerning for several reasons. First, older patients are more vulnerable
to experiencing polypharmacy and adverse drug events. Second, nursing home patients are
frailer with more comorbidities, making them a subset of the population with the potential
to experience the most harm from using multiple HPA and the most benefit from the NHS
prescribing advice. Most likely, the increase in anticholinergic burden is due to HPA
medications used for symptomatic control, such as antipsychotics for delirium and
antispasmodics for urinary incontinence. Therefore, deprescribing may not be possible,
explaining the lack of relative risk reduction in this population. Moving forward, nursing
home patients over 85 years old may benefit from additional medication reviews to
determine if HPA medicines prescribed are inappropriate. As well, it may also be that the
older nursing home population was not appropriately targeted by the NHS prescribing
advice, with younger patients benefiting more. Finally, the NHS may need to implement a
more specific effort aimed at older nursing home patients.

Limitations:
As a review of a prescription claims database, this study has several limitations.
First, this study could not identify the indications, dosages, or quantity prescribed with
the HPA prescriptions. The presumed anticholinergic burden varies based on duration,
dosage, or frequency of HPA medication use. These omissions limit the ability of this
analysis to separate which medications were given as needed, potentially having a
smaller effect of anticholinergic burden, versus more significant chronic therapies.
Second, this dataset was unable to link the prescription of HPA medications to adverse
patient outcomes. So, while this study inferred based on previous biological and clinical
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studies that an increase in anticholinergic burden lead to an increase in side effects, this
analysis was unable to demonstrate this phenomenon. Finally, nursing home and
community patients are different in that nursing home patients are more likely to have
complex comorbid conditions causing an increase in the number of prescriptions. One
must consider this fundamental difference when drawing conclusions from this analysis.

Further Directions:
Building off the NHS NTI, this analysis demonstrated which patient populations
benefited most and the least from the NHS prescribing advice on anticholinergics. With
this study as a baseline, there are future pathways to determine how to improve NHS
guidance on HPA prescribing. To aid in determining why the NHS prescribing advice
was ineffective in nursing home patients aged 85 and older, further analysis could break
this data down by individual HPA medications. This stratification may identify which
medications are driving the increase in risk. Additionally, stratifying both community and
nursing home patients by other factors such as gender, NHS health board, and HPA
medication class may provide insight into which patients remain on HPA medications
despite the NHS prescribing advice. Finally, this study analyzed only those patients with
the highest anticholinergic burden. Further analysis could expand on this data by looking
at patients with any degree of anticholinergic burden risk.
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Conclusion:
From 2015 to 2017, Scottish NHS recommended against prescribing HPA to
elderly patients, and deprescribe unnecessary HPA medications. This analysis shows the
majority of elderly patients in Q2'2016-Q1'2017 residing in nursing homes and the
community experienced less risk of receiving ≥2HPA prescriptions in comparison to
patients Q2'2011-Q1'2012. Then from Q2'2016-Q1'2017 to Q2'2018-Q1'2019 the relative
risk reduction plateaued. These trends suggest the beneficial effect of the NHS
prescribing advice. Nursing home patients aged 85 and older in Q2'2018-Q1'2019
showed more risk of receiving ≥2HPA prescriptions in comparison to patients in
Q2'2016-Q1'2017, suggesting that patients aged ≥85 in nursing homes are at risk for a
higher anticholinergic burden, did not benefit from the NHS prescribing advice, and
should be targeted for further action.
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Appendix 1.
1. Amitriptyline
2. Amitriptyline HCl with perphenazine
3. Atropine sulfate
4. Benztropine mesylate
5. Chlorphenamines maleate
6. Clemastine
7. Clomipramine HCl
8. Clozapine
9. Cyproheptadine HCl
10. Darifenacin
11. Desipramine HCl
12. Doxepin
13. Epinephrine, Atropine, and papaverine
14. Flavoxate HCl
15. Fluphenazine Deaconate
16. Fluphenazine Enanthate
17. Fluphenazine HCl
18. Hydroxyzine Embonate
19. Imipramine HCl
20. Levomepromazine
21. Morphine with Atropine
22. Nortriptyline
23. Nortriptyline with Fluphenazine
24. Orphenadrine Citrate
25. Oxybutynin HCl
26. Phenylpropanolamine with Clementine
27. Procyclidine HCl
28. Promethazine HCl
29. Promethazine Teoclate
30. Thioridazine
31. Tizanidine HCl
32. Tolterodine
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